29th CINP WORLD CONGRESS OF NEUROPSYCHOPHARMACOLOGY · 2017-06-22 · 29th CINP WORLD CONGRESS OF NEUROPSYCHOPHARMACOLOGY CInP – The International College of neuropsychopharmacology

29th CINP WORLD CONGRESS OF NEUROPSYCHOPHARMACOLOGYCInP – The International College of neuropsychopharmacology

22 – 26 June 2014Vancouver

Canada

22 – 26 June 2014Vancouver

www.cinp2014.com www.cinp.org

Call for Posters | Registration

Preliminary Scientifi c Programme

2

29th CINP World CoNgress 2014

Table of ConTenT page

Welcome address 3

brief Description of CInP / Committees and organisers 4

Scientific Information – format Descriptions 5

Preliminary Scientific overview 6

brief biography of Plenary Speakers 8

Preliminary Scientific Programme 11

Call for Poster abstracts 22

Topics / CMe accreditation 23

CInP awards 24

Congress Registration 26

General Information 28

application forms for CInP awards Registration form

CInP and Congress PresidentProfessor anthony PhillipsDepartment of PsychiatryUniversity of british Columbia430-5950 University blvd. Vancouver, bC, Canada, V6T 1Z3

Host organisation – CInP Central officeGlenfinnan Suite, braeview House9 / 11 braeview Place, east KilbrideGlasgow G74 3XH, Scotland, UKPhone: +44 (0) – 1355 244 930fax: +44 (0) – 1355 249 959email: [email protected]

Congress office

Hamburg officeHanser & Co GmbHZum ehrenhain 3422885 barsbüttel, GermanyPhone: +49 – 40 – 670 88 20fax: +49 – 40 – 670 32 83email: [email protected]

Congress VenueVancouver Convention Centreeast Wing1055 Canada PlaceVancouver, bC, V6C 0C3, Canada

DaTeS To ReMeMbeR

10 January 2014ll Deadline for awards nominations

5 February 2014 ll first deadline for early registration feell Deadline for poster abstract submission

20 May 2014 ll Second deadline for registration fee

22 June 2014 ll opening Ceremony of CInP 2014

3


Highlights of the 2014 CInP World Congress

Dear Colleagues,

CInP-Vancouver 2014 is less than 12 months away and I urge you to prepare your abstracts, make the necessary travel plans and take advantage of early registration rates.

The most compelling reason to choose CInP-Vancouver 2014, as the destination for your major in-ternational professional activity next year is the quality of the Scientific Program. as highlighted in this announcement you can select from a wide range of topics of immediate relevance to neuropsycho-pharmacology as focused on both discovery and clinical practice. Thirty-six symposia form the nucleus of the program and they are complimented with Plenary lectures by renowned colleagues whose discoveries, involving optogenetics, precise descriptions of receptor and transporter func-tion, novel neurotransmitters or innovations in clinical practice, are transforming the treatments of devastating psychiatric and neurological conditions.

We have paid particular attention to your comfort, health and safety during your stay. a recent sur-vey by the economist Intelligence Unit ranked Vancouver as the 3rd most livable city overall, for the second year in a row. Similarly, many of the hotels reserved for your accommodation are amongst the best in the world and are located within a short distance from the Convention Centre. Walking and cycling are encouraged by a continuous public seawall that links the meeting place with the perimeter of Stanley Park, a green jewel at the doorstep of downtown Vancouver.

I hope all that CInP-Vancouver 2014 has to offer will intrigue you and I look forward to welcoming you and your colleagues from around the globe to another memorable CInP World Congress.

See you in June 2014!

best wishes,

WelCoMe aDDReSS

anthony Phillips

Prof. anthony PhillipsCINP and Congress President

Prof. brian DeanChair of the CINP InternationalScientific Programme Committee

brian Dean

4


The International College of neuropsychopharmacology (CInP) is a truly worldwide organisation established over 50 years ago with its registered office in Zurich, Switzer-land. Membership is on an individual basis and we offer members the opportunity to become part of this know-ledgeable group of scientists who work at the international level. Holding regular meetings in the form of Thematic Meetings, Regional Meetings, Training Programmes, Think Tank and the biennial World Congress, CInP reaches inter-ested researchers all over the world. CInP is dedicated to promoting research and education on a worldwide basis.

The executive Committee and Councillors of CInP are nom-inated by the membership and serve as officers of the Col-lege for a minimum of four years. These individuals cover a wide range of disciplines within the field from psychiatrists,

CInP executive Committee 2012 – 2014 Presidentanthony Phillips, Canada

Past PresidentHans-Jürgen Möller, Germany

Vice PresidentJeffrey lieberman, USaalexandra Sulcova, Czech Republic

President Elect Shigeto Yamawaki, Japan

Secretary Siegfried Kasper, austria

Treasurerbrian Dean, australia

CouncillorsPhilip J. Cowen, UKelias eriksson, Swedenalan frazer, USanancy Y. Ip, Hong KongKlaus-Peter lesch, GermanyPhilip Mitchell, australiaDan Rujescu, Germanybarbara Sahakian, UKToshikazu Saito, JapanGustavo Turecki, CanadaGregers Wegener, Denmark

CInP International Scientific Programme Committtee Chair: brian Dean, australiaCo-Chair: Pierre blier, Canada

Philip J. Cowen, UKelias eriksson, Swedenalan frazer, USaanthony Grace, USanancy Y. Ip, Hong KongShitij Kapur, UKSiegfried Kasper, austriaJun Soo Kwon, KoreaKlaus-Peter lesch, GermanyMarco leyton, CanadaJeffrey lieberman, USabrian MacVicar, CanadaPhilip Mitchell, australiaHans-Jürgen Möller, Germanyanthony Phillips, CanadaDan Rujescu, Germanybarbara Sahakian, UKToshikazu Saito, Japanalexandra Sulcova, Czech RepublicGustavo Turecki, CanadaGregers Wegener, DenmarkShigeto Yamawaki, Japan

local organising Committee Chairs: lakshmi Yatham, Vancouver Michael Krausz, Vancouver

Glen baker, edmontonPierre blier, ottawaStan floresco, VancouverWilliam Honer, VancouverXin-Min li, edmontonbrian MacVicar, Vancouveranthony Phillips, VancouverChristian Schutz, VancouverSamuel Weiss, Calgary

bRIef DeSCRIPTIon of CInP / CoMMITTeeS anD oRGanISeRS

psychopharmacologists, basic and clinical researchers and clinical psychologists. CInP relies on its many subcommit-tees who undertake a variety of activities for the College.

Membership of the College is available to any qualified per-son to apply for. Membership applications are reviewed by a dedicated committee on a regular basis.

The International Journal of neuropsychopharmacology (IJnP) with a steadily increasing impact factor, has become a sought after publication. articles are received and re-viewed independently and are published after a rigorous review process.

for more information about the College please go to our interactive website at www.cinp.org

5


SCIenTIfIC InfoRMaTIon – foRMaT DeSCRIPTIonS

Plenary lecturesPlenary lecturers present 45-minute talks to highlight spe-cific topics featured to the ensuing morning and afternoon session, each day of the congress. These speakers are cho-sen in recognition of their exceptional achievements in basic or clinical research. Their lectures will include material of interest to both basic and clinical scientists as well as to a broad clinical audience.

SymposiaSymposia of two-hour duration integrate the latest ad-vances in basic and clinical neuropsychopharmacology, biological psychiatry, drug development, public policy is-sues relevant to mental health, mental illness and treat-ment across the lifespan.

Pro and Con DebatesDuring the daily 90-minute debates current controversial issues will be introduced and discussed. one moderator and two discussants (pro and con) will raise interactive and lively debates.

educational and Scientific Workshopseducational and Scientific Workshops are sessions, which typically involve brief presentations from individual panel members, followed by the opportunity for lively and infor-mative discussion. This format provides substantial audi-ence participation in education and science and should be highly interactive.

Poster SessionsThese sessions offer an effective forum for the exchange of information and a means to communicate ideas, re-search, and programmes. Poster authors will present and discuss their results in these highly interactive sessions in various fields.

Satellite SymposiaSatellite symposia will be organised and presented by phar-maceutical companies in consultation with the International Scientific Programme Committee. breakfast, lunch and eve-ning symposia are scheduled for 60 or 90 minutes.

DateTime

Sunday22 June 2014

Monday23 June 2014

Tuesday24 June 2014

Wednesday25 June 2014

Thursday26 June 2014

07:45 – 08:45 Morning Industry Satellite Symposia

09:00 – 09:45 Plenary Lecture 09:00 – 11:10 Symposia09:45 – 10:00 Coffee break

10:00 – 12:10 Symposia, Debates, Educational and Scientific Workshops

11:00 – 11:15 Coffee break

11:15 – 12:00 Plenary Lecture

12:15 – 13:45 12:15 – 13:45 Industry Satellite Symposia

12:00 – 14:00 Lunch BreakClosing

14:00 – 14:45 Plenary Lecture

14:45 – 15:00 Coffee break

15:00 – 17:10 Symposia, Debates, Educational and Scientific Workshops

17:15 – 18:45 Industry Satellite Symposia

Poster Tours Opening & Welcome

18:00 – 21:3018:45 – 21:30

overview at a Glance

6


Monday, 23 June 2014

09:00 – 09:45 Pl-1The arvid Carlsson lecture: The ups and downs of amphetamines: a diversity of actions on cellular signaling pathways

10:00 – 11:00 W-1 The pitfalls, problems using gene knockout animals in neuropsychopharmacology (Scientific)

10:00 – 12:00

S-1 Remodeling the neurocircuitry of depression: Ketamine and glutamate

S-2 neuron-glia interaction in schizophrenia: focus on D-serine

S-3 Developing novel drug classes for bipolar disorder

S-4 Paediatric disorders characterised by aggression and/or social impairment: from preclinical research to clinical subtyping

S-5 alcohol dependence: neuroimaging and pharmacology

JS-1 Japanese Session

11:10 – 12:10 W-2 The use of psychotropic drugs during pregnancy and breast feeding (educational)


14:00 – 14:45 Pl-2 nobel lecture: Structural insights into G protein coupled receptor signaling

15:00 – 16:00 W-3 Managing treatment resistance in psychiatry (educational)

15:00 – 16:30 P/C-1 lithium is no longer needed as a mood stabiliser

15:00 – 17:00

S-6 emerging neuromechanisms for the treatment of depression: Insights from animal and human studies

S-7allosteric modulators of metabotropic glutamate receptors (mGlu) as novel tools for the treatment of CnS disorders

S-8 obsessive-compulsive and related disorders: a translational approach

S-9 neuroimaging vulnerability to neuropsychiatric disorders

S-10 Coming of age for phosphodiesterase inhibitors as central nervous system therapeutics

16:10 – 17:10 W-4 GPCRs and psychotherapeutic drug development (Scientific)

Tuesday, 24 June 201409:00 – 09:45 Pl-3 The importance of being an endocannabinoid

10:00 – 12:00

S-11 The potential of high-risk studies to inform early intervention in bipolar disorder

S-12 Targeting the endocannabinoid system to treat psychiatric disorder: Clinical and pre-clinical evidence

S-13 The epigenetic embedding of early life stress in humans and animal models

S-14 Prefrontal norepinephrine in arousal and executive function

S-15 baCe1 in alzheimer’s disease pathogenesis and drug development

10:00 – 11:00 W-5 Understanding modern genetics (educational)

10:00 – 12:00 KS-1 Korean Session

11:10 – 12:10 W-6 optimising drug trial design (educational)


14:00 – 14:45 Pl-4 brain science using ips cell technology and transgenic non-human primates

15:00 – 16:30 P/C-2 DSM5 will be the Death of Psychopharmacology

15:00 – 17:00

S-16 new basic and clinical developments for treatment resistant depression

S-17 novel glutamatergic treatment approaches for schizophrenia: Pharmacology, imaging and clinical trials

S-18 breakthroughs in psychopharmacology for prevention and treatment of PTSD

S-19 The psychopharmacology of aggression: from biomarkers to therapeutics

S-20 Remodeling synaptic connections in the pathophysiology and treatment of depression

15:00 – 16:00 W-7 Treatment of aDHD across the lifespan (educational)

16:10 – 17:10 W-8 Translating schizophrenia to animal models: What works and what doesn’t (educational)

PRelIMInaRY SCIenTIfIC oVeRVIeW

18:00 – 21:30 opening Ceremony and Welcome Reception

Sunday, 22 June 2014

7


Wednesday, 25 June 201409:00 – 09:45 Pl-5 Clinical Staging: Towards utility in diagnosis and clarity in neurobiology understanding in psychiatry

10:00 – 11:30 P/C-3 Personalised medicine: fact or fantasy

10:10 – 11:30 W-9 Pathways to CnS drug discovery (Scientific)

10:00 – 12:00

S-21 Personalized medicine in mood and anxiety disorders

S-22 Is schizophrenia a progressive disease?

S-23 Psychiatric disorders, 24-hour circadian rhythms: Clock genes and new treatment implications

S-24 Gut microbiota and brain function: Relevance to psychiatric disorders

S-25 The expanding roles of microglia in chronic pain: Implications for therapy


14:00 – 14:45 Pl-6 optical deconstruction of fully-assembled biological systems

15:00 - 16:30 P/C-4 antidepressants act to induce neurogenesis in the adult brain

15:00 - 16:30 W-10 opto genetics (Scientific)

15:00 – 17:00

S-26 Depression in pregnancy and postpartum: a treatment dilemma?

S-27 a new nomenclature proposal for psychotropic drugs

S-28 Serotonin, stress and depression: genetic and epigenetic factors

S-29 Clinically useful biomarkers in psychiatry: The promise and problem

S-30brain-Derived neurotrophic factor (bDnf) and synaptic plasticity as a drug target for cognitive dysfunction in CnS disorders

PRelIMInaRY SCIenTIfIC oVeRVIeW

Colour Topic

anxiety Disorder

attention Deficit Disorders

biomarkers

bipolar Disorder

Clinical Inv; national fund agency

Depression

elias eriksson Symposium

neurodegenerative Disorders

Thursday, 26 June 201409:00 – 10:00 W-11 The abC’s and CpGs of epigenetics (educational)

09:00 – 11:00

S-31 Polypharmacy in psychotic and affective disorders: Co-medication with antipsychotic and antidepressant drugs

S-32 new insights into the role of nMDa receptors in cognition and psychosis

S-33 Converting biological findings into routine clinical tests – psychiatry’s next big challenge

S-34 novel therapeutics

S-35 adult aDHD and obesity: neurotransmitter imaging and pharmacotherapies targeting impulsivity

S-36 Synaptic plasticity and neurodegeneration

10:10 – 11:10 W-12 The impact of neuroimaging on understanding psychiatric disorders

11:15 – 12:00 Pl-7 CInP/CCnP lecture: Interactions between neurotransmitters: The key to remission for depression

Colour Topic

neuroimaging

Pain

Post-traumatic Stress Disorder

Psychoneuroimmunology and neuroinflammation

Schizophrenia

Abbreviations

Pl – Plenary lecture S – Symposium

W – Workshop P/C – Pro-Con Debate

8


bRIef bIoGRaPHY of PlenaRY SPeaKeRS

MonDaY, 23 JUne 2014 09:00 – 09:45

Pl-01 earvid Carlsson lecture The ups and downs of amphetamines: a diversity of actions on cellular signaling pathwaysSusan G. Amara, USA Susan G. amara is the Scientific Director of the nIMH intramural research program at nIH. Work in her laboratory has focused on the structure, function, and cellular physiology of neurotransmitter transporters, including the biogenic amine transporters, major targets for psychostimulant drugs and antidepressants. She received a bS in biological Sciences from Stanford University and a PhD in Physiology and Pharmacology from the University of California, San Diego and has previously held faculty positions at Yale University School of Medicine, at the Vollum Institute in Portland, oregon and as a Howard Hughes Medical Institute Investigator at Yale and in oregon. amara has received the burroughs Wellcome Hitchings award in drug discovery, the Society for neuroscience Young Investi-gator award, the aSPeT John Jacob abel award, a McKnight neuroscience Investigator award, a MeRIT award from nIDa, a naRSaD Distinguished Investigator award, and the Julius axelrod award from the Catecholamine Society. She is an elected member of the national academy of Sciences (2004), a fellow of the aaaS (2007) and is a past-President of the Society for neuroscience (2011).

MonDaY, 23 JUne 2014 14:00 – 14:45

Pl-02 enobel lecture Structural insights into G protein coupled receptor signalingBrian Kobilka, USA Dr. Kobilka received bachelor of Science Degrees in biology and Chemistry from the University of Minnesota, Duluth in 1977. He graduated from Yale University School of Medicine in 1981, and completed residency training in Internal Medicine at the barnes Hospital, Washington University School of Medicine, St. louis, Missouri in 1984. from 1984 – 1989 he was a postdoctoral fellow in the laboratory of Robert lefkowitz at Duke University. In 1990 he joined the faculty of Medicine and Molecular and Cellular Physiology at Stanford University. He was promoted to Professor of Medicine and Molecular and Cellular Physiology in 2000. Research in the Kobilka lab focuses on the structure and mechanism of action of G protein coupled receptors (GPCRs), which constitute the largest family of receptors for hormones and neurotransmitters in the human genome. GPCRs are the largest group of targets for new therapeutics for a very broad spectrum of diseases.

TUeSDaY, 24 JUne 2014 09:00 – 09:45

Pl-03 ePlenary lecture The importance of being an endocannabinoid Raphael Mechoulam, Israel Prof. Mechoulam received his Masters Degree in biochemistry from the Hebrew University in 1952 and his Ph.D. from the Weizmann Institute in 1958 where he studied under Professor f. Sondheimer. He completed his postdoctoral research at the Rockefeller Institute. Dr. Mechoulam is currently with the Institute for Drug Research at the faculty of Medicine at the Hebrew University in Jerusalem. He is former Rector of the University and is a member of the Israel academy of Sciences. Dr. Mechoulam has received many honours, including honorary doctorates from Spain and USa, the Israel Prize in 2000 and the european College of neuropsychopharmacology lifetime achievement award in 2006. In 2012, he received the Rothschild Prize. His research interests are in the field of the chemistry and biological activity of natural products and medicinal agents. His main contributions are in the field of the constituents of cannabis and the endogenous cannabinoids found in the brain and the periphery. He has published extensively on their pharmacological activities.

Susan G. amara

brian Kobilka

Raphael Mechoulam

9



TUeSDaY, 24 JUne 2014 14:00 – 14:45

Pl-04 ePlenary lecture brain science using iPS cell technology and transgenic non-human primatesHideyuki Okano, Japan Hideyuki okano received a M.D. in Physiology from Keio University in 1983, and served as a re-search associate in Keio University School of Medicine and in osaka University Institute for Protein Research. after he obtained his Ph.D. degree from Keio University in 1988, he held a post doctoral position at Johns Hopkins University Medical School. He was appointed a full professor at Tsukuba University School of Medicine in 1994, osaka University School of Medicine in 1997, and returned to Keio University Medical School in 2001 as a full professor of Physiology. He has been conducting basic research in the field of restorative medicine including, neural stem cells and iPS cells, spinal cord injury, developmental genetics and Rna binding proteins. He has been awarded numerous awards and honors including the Medal with Purple Ribbon in 2009. Currently, his aim is to estab-lish and provide genetically modified non-human primate models for neuroscience research and to explore the molecular mechanisms of human-intellectual function by using the marmoset model. and, together with micro array system and genome sequence information of common marmoset, he is trying to develop a wide range of research as a model of human diseases including Parkinson’s disease, alS and alzheimer’s diseases, neurophysiology, cognitive science and higher brain func-tion research by taking advantage of our transgenic technology, thereby addressing discrete ques-tions regarding neurobiological bases of human-intellectual function.

WeDneSDaY, 25 JUne 2014 09:00 – 09:45

Pl-05 ePlenary lecture Clinical staging: Towards utility in diagnosis and clarity in neurobiological understanding in psychiatryPatrick D. McGorry, Australia Patrick D. McGorry is Professor of Youth Mental Health at the University of Melbourne and Director of orygen Youth Health and orygen Youth Health Research Centre in Victoria, australia. Prof. Mc Gorry is a world-leading clinician, researcher, and reformer in the areas of early psychosis, early intervention and youth mental health. Prof. McGorry’s work has played an integral role in the development of safe, effective treatments and innovative research involving the needs of young peo-ple with emerging mental disorders, notably psychotic and severe mood disorders. The result has been the creation, evaluation and upscaling of stigma-free, holistic and recovery oriented models of care for young people and their families. The work of Prof. McGorry and key research colleagues at ePPIC, orygen and headspace has influenced health policy in australia and many other countries. Prof. McGorry has published over 500 peer-reviewed papers and reviews, over 60 book chapters, and has edited 6 books. He is a fellow of the academy of the Social Sciences in australia and has been the recipient of numerous awards, including the australian Government Centenary Medal in 2003, the founders’ Medal of the australian Society for Psychiatric Research in 2001 and he was the 2010 australian of the Year. He is current President of the australasian Society for Psychiatric Research.

Patrick McGorry

Hideyuki okano

10



WeDneSDaY, 25 JUne 2014 14:00 – 14:45

Pl-06 ePlenary lecture optical deconstruction of fully-assembled biological systemsKarl Deisseroth, USA Karl Deisseroth is the D.H. Chen Professor of bioengineering and Psychiatry at Stanford University. He earned his a.b. from Harvard and M.D./Ph.D. from Stanford, serves as Director of Undergraduate education in bioengineering at Stanford, and is a practicing psychiatrist board-certified by the american board of Psychiatry and neurology. He has developed and applied novel technologies for controlling (optogenetics) and imaging (ClaRITY) specific elements within intact biological systems, and continues to develop and apply new technologies to study physiology and behavior in health and disease, as well as train researchers around the world. He has received the nIH Pioneer award (2005), Scheutze Prize (2008), Society for neuroscience Young Investigator award (2009), Koetser Prize (2010), nakasone Prize (2010), Spencer Prize (2011), UnC/Perl Prize (2012), Zuelch Prize (2012), Pasarow Prize (2013), bRaIn prize (2013) and lounsbery Prize (2013). Deisseroth is a member of the Institute of Medicine and the national academy of Sciences.

THURSDaY, 26 JUne 2014 11:15 – 12:00

Pl-07 eCInP/CCnP lecture Interactions between neurotransmitters: The key to remission for depressionPierre Blier, Canada Dr. blier is a full Professor of the Departments of Psychiatry and Cellular & Molecular Medicine, at the University of ottawa, and Director of the Mood Disorders Research Program at the University of ottawa Institute of Mental Health Research, Royal ottawa Mental Health Care Center.Dr. blier is on the editorial boards of nine journals, the field editor for Translational Medicine for International Journal of neuropsychopharmacology, and the editor for the americas of the Journal of Psychopharmacology. Has published over 450 abstracts and 270 peer-reviewed articles (h factor of 62) and has given lectures worldwide. He has a basic research laboratory investigating mecha-nisms of action of psychotropic medications, carries out investigator-initiated clinical studies, and treats patients with mood and anxiety disorders on a daily basis.Dr. blier has received several awards including the Canada Research Chair in Psychopharmacology (2004-2018) from the Government of Canada and the biennial CInP basic Research award in 2010.

Karl Deisseroth

Pierre blier

11


Monday, 23 June 2014 | PRelIMInaRY SCIenTIfIC PRoGRaMMe

PL-01 eArvid Carlsson Lecture 09:00 – 09:45

The ups and downs of amphetamines: a diversity of actions on cellular signaling pathwaysSusan G. Amara, USA

S-1 eSymposium 10:00 – 12:00

Topic: Depression (a) Track: Translational

Remodeling the neurocircuitry of depression: Ketamine and glutamateChair: Anthony Grace, USA Co-chair: Rupert Lanzenberger, Austria

Current treatments of depression: Impact on monoamines and glutamatePierre blier, Canada

Results of brain imaging (f-MRI) of Ketamine Rupert lanzenberger, austria

Prefrontal-amygdala attenuation of dopamine neuron activ-ity in animal models of depression: Reversal by Ketamineanthony Grace, USa

Too little or too much? The place of glutamate in depressionMaurizio Popoli, Italy

S-2 eSymposium 10:00 – 12:00

Topic: Schizophrenia (a) Track: basic

neuron-glia interaction in schizophrenia: focus on D-serineChair: Mikhail Pletnikov, USA Co-chair: Toru Nishikawa, Japan

Neuron-glia regulation of D-serine signaling: Implication in schizophreniaToru nishikawa, Japan

D-Serine localization: Fact or artifactJoseph Coyle, USa

Contribution of the neuronal Asc-1 transporter for D-ser-ine dynamics: Implications for schizophreniaHerman Wolosker, Israel

DISC1-serine racemase interaction in astrocytes: At the intersection of two major pathways of schizophreniaMikhail Pletnikov, USa

S-3 eSymposium 10:00 – 12:00

Topic: bipolar disorder (a) Track: basic

Developing novel drug classes for bipolar disorder Chair: Tadafumi Kato, Japan Co-chair: Husseini Manji, USA

A strategy for drug development of bipolar disorderTadafumi Kato, Japan

Roles of genetics-based animal models in drug develop-ment in bipolar disorderTracey Petryshen, USa

Russian doll approach for drug development in bipolar disorderHusseini Manji, USa

Ebselen as a novel IMPase inhibitor as a lithium mimeticGrant Churchill, United Kingdom

S-4 eSymposium 10:00 – 12:00

Topic: attention deficit disorders (D) Track: Translational

Paediatric disorders characterised by aggression and /or social impairment: from preclinical research to clinical sub-typing Chair: Klaus-Peter Lesch, The Netherlands Co-chair: Steve Faraone, USA

Epidemiology and large-scale multi-center genetic stud-ies in ADHD and conduct disorderSteve faraone, USa

Gene-by-environment interaction and epigenetic mecha-nisms in aggression: Lessons from animal modelsKlaus-Peter lesch, The netherlands

Genetics of adult ADHD and antisocial personality dis-orderandreas Reif, Germany

Overlap and differences between ADHD and conduct disorder: Imaging genetics approachesbarbara franke, The netherlands

12


PRelIMInaRY SCIenTIfIC PRoGRaMMe | Monday, 23 June 2014

S-5 eSymposium 10:00 – 12:00

Topic: neuroimaging (b) Track: Translational

alcohol dependence: neuroimaging and pharmacologyChair: Andrew J. Greenshaw, Canada Co-chair: Wolfgang Sommer, Germany

Mapping of functional brain activity in alcohol drinking rats using manganese-enhanced magnetic resonance imagingPetri Hyytiä, finland

Increased brain activity during protracted abstinence as a predictor for relapse behaviour in alcohol dependent ratsWolfgang Sommer, Germany

Alcohol use disorder: Structural and functional brain changes in abstinence and effects of naltrexoneandrew J. Greenshaw, Canada

NK1 and dopamine D3 antagonists as new approaches to alcohol dependenceDavid nutt, United Kingdom

W-1 eScientific Workshop 10:00 – 11:00

The pitfalls, problems using gene knockout animals in neuro-psychopharmacology

W-2 eEducational Workshop 11:10 – 12:10

The use of psychotropic drugs during pregnancy and breast feeding

Japanese Session 10:00 – 12:00

PL-02 eNobel Lecture 14:00 – 14:45

Structural insights into G protein coupled receptor signalingBrian Kobilka, USA

S-6 eSymposium 15:00 – 17:00

Topic: Depression (a)Track: Translational

emerging neuromechanisms for the treatment of depression: Insights from animal and human studiesChair: Athina Markou, USA Co-chair: Ronald Duman, USA

Role of mTOR signaling and synaptogenesis in the re-sponse to rapid acting antidepressantsRonald Duman, USa

Resilence and susceptibility to stress: Predictors of re-sponse to antidepressants and Ketamineathina Markou, USa

Neuropeptide receptors as targets for drug discovery for the treatment of depressionShigeyuki Chaki, Japan

Rewiring faulty circuits: The promise of deep brain stim-ulation for severe major depressionThomas Schlaepfer, Germany

S-7 eSymposium 15:00 – 17:00


allosteric modulators of metabotropic glutamate receptors (mGlu) as novel tools for the treatment of CnS disordersChair: Andrzej Pilc, Poland Co-chair: P. Jeffrey Conn, USA

Therapeutic implications of diverse modes of efficacy and stimulus bias of allosteric modulators of mGlu receptorsP. Jeffrey Conn, USa

Design, synthesis and evaluation of Novel Group II Metabotropic Glutamate Receptor Allosteric Modulators in rodent models of CNS disordersnicholas D. P. Cosford, Poland

The antipsychotic activity of allosteric vs./orthosteric agonists of mGlu4 receptorsandrzej Pilc, Poland

Metabotropic glutamate and GABA receptors in fragile X syndromeDavid R. Hampson, Canada

S-8 eSymposium 15:00 – 17:00

Topic: anxiety disorders (a) Track: Translational

obsessive-compulsive and related disorders: a translational approachChair: Dan Stein, South Africa Co-chair: Anthony Grace, USA

Rodent models of OCD and the role of dopaminergic neuronsanthony Grace, USa

The streptococcal model of obsessive-compulsive and related disordersDaphna Joel, Israel

13

29th CInP WoRlD ConGReSS 2014

Monday, 23 June 2014 | PRelIMInaRY SCIenTIfIC PRoGRaMMe

Inukshut at Sunset – Tourism Vancouver

Current perspectives on compulsivityTrevor Robbins, United Kingdom

Clinical advances in obsessive-compulsive and related disordersDan Stein, South africa

S-9 eSymposium 15:00 – 17:00

Topic: neuroimaging (b)Track: Translational

neuroimaging vulnerability to neuropsychiatric disordersChair: Marco Leyton, CanadaCo-chair: Phil J. Cowen, United Kingdom

Using neuroimaging to identify neural markers of famil-ial vulnerability to depressionPhil J. Cowen, United Kingdom

Neuroimaging the vulnerability to depression: The glu-tamate systemGregor Hasler, Switzerland

What underlies the onset of psychosis? Multi-modal and longitudinal imaging data from people at risk of psychosisoliver D. Howes, United Kingdom

PET studies of dopamine responses in subjects at risk for substance use disordersMarco leyton, Canada

PC-1 ePro-Con Debate 15:00 – 16:30

lithium is no longer needed as a mood stabiliser


Managing treatment resistance in psychiatry

W-4 eScientifi c Workshop 16:10 – 17:10

GPCRs and psychotherapeutic drug development

S-10 eSymposium 15:00 – 17:00

Topic: neurodegenerative disorders: Parkinson, alzheimer, Huntington, fronto-Temporal Dementia, Vascular Dementia (a)Track: Translational

Coming of age for phosphodiesterase inhibitors as central nervous system therapeuticsChair: Jos Prickaerts, The NetherlandsCo-chair: Lawrence Wennogle, USA

Role of PDE-mediated signaling and its crosstalk in brain functionakinori nishi, Japan

Role of cyclic nucleotides in cognitive function in the brainlawrence Wennogle, USa

PDE4 and PDE5 inhibitors in cognition enhancement: From animals to humans and back againJos Prickaerts, The netherlands

Differential effects of PDE2, 4, 9 and 10 inhibition on biochemical and behavioral markers of striatal functionChristopher Schmidt, USa

14


PRelIMInaRY SCIenTIfIC PRoGRaMMe | Tuesday, 24 June 2014

PL-03 ePlenary Lecture 09:00 – 09:45

The importance of being an endocannabinoid Raphael Mechoulam, Israel

S-11 e Symposium 10:00 – 12:00

Topic: bipolar disorder (a) Track: Clinical

The potential of high-risk studies to inform early interven-tion in bipolar disorderChair: Philip Mitchell, Australia Co-chair: John Nurnberger, USA

Use of genetic and clinical variables for clinical interven-tion in subjects at risk for bipolar disorderJohn nurnberger, USa

The clinical trajectory into bipolar disorder: Targeting early intervention in high-risk youthanne Duffy, Canada

What interventions can be used in high risk offspring? An evidence map of currently available therapies, and their potential for preventing disease onset or progressionJan Scott, United Kingdom

Using brain imaging and genetics to identify those at high risk for bipolar disorderPhilip Mitchell, australia

S-12 eSymposium 10:00 – 12:00

Topic: Schizophrenia (a) Track: Translational

Targeting the endocannabinoid system to treat psy chiatric disorders: Clinical and pre-clinical evidenceChair: Elizabeth Scarr, Australia Co-chair: Brian Dean, Australia

CB1 receptor imaging provides a model for evidence-based treatment development in post-traumatic stress disorderalexander neumeister, USa

A homeostatic role for the endocannabinoid system in schizophreniaf. Markus leweke, Germany

Cannabinoid receptors in the human CNS: Changes in psychotic disordersbrian Dean, australia

What do CB1 knockout mice tell us about the endocan-nabinoid system elizabeth Scarr, australia

S-13 eSymposium 10:00 – 12:00


The epigenetic embedding of early life stress in humans and animal modelsChair: Marco Andrea Riva, Italy Co-chair: Moshe Szyf, Canada

Epigenetic signature of life adversities in utero and long-term consequence for mental illnessMarco andrea Riva, Italy

Early life stress and genome wide adaptationMoshe Szyf, Canada

Activation of the Glucocorticoid Receptor: A possible mediator of genome-wide changes in DNA-methylation following early traumaelisabeth binder, Germany

Prenatal exposure to a natural disaster and life long health risksSuzanne King, Canada

S-14 eSymposium 10:00 – 12:00


Prefrontal norepinephrine in arousal and executive functionChair: David Morilak, USA Co-chair: Gary Aston-Jones, USA

Functional network effects of selective LC-NE stimulationGary aston-Jones, USa

Monoaminergic regulation of impulsivity and gambling-related decision-making Catharine Winstanley, Canada

The dual role of norepinephrine in modulating cognitive flexibility in prefrontal cortex: Acute facilitation and chronic stress-induced attenuationDavid Morilak, USa

Noradrenergic modulation of cognitive control and atten-tion in rodents and humans; translational implicationsTrevor Robbins, United Kingdom

15


Tuesday, 24 June 2014 | PRelIMInaRY SCIenTIfIC PRoGRaMMe

S-15 eSymposium 10:00 – 12:00

Topic: neurodegenerative disorders: Parkinson, alzheimer, Huntington, fronto-Temporal Dementia, Vascular Dementia (a) Track: Translational

baCe1 in alzheimer’s disease pathogenesis and drug developmentChair: Weihong Song, Canada Co-chair: Jianping Jia, People’s Republic of China

GSK3 signaling regulates BACE1 expression and APP processing and its pharmaceutical potential for Alzheim-er’s disease drug developmentWeihong Song, Canada

Alteration of BACE1 processing of APP in Alzheimer’s diseaseKari Stefansson, Iceland

Inhibition of BACE1 for benefiting AD patientsRuqiang Yan, USa

BACE1 SNPs and clinical trials in ChinaJianping Jia, People’s Republic of China


Understanding modern genetics


optimising drug trial design

Korean Session 10:00 – 12:00


brain science using iPS cell technology and transgenic non-human primatesHideyuki Okano, Japan

S-16 eSymposium 15:00 – 17:00


new basic and clinical developments for treatment Resistant DepressionChair: Alan Frazer, USA Co-chair: Siegfried Kasper, Austria

Drug development in treatment-resistant depression: Current progress, major hurdles and future strategiesCarlos Zarate, USa

TRD: Results of a European multi-centre studySiegfried Kasper, austria

Potential of mGlu2/3 receptor antagonists for treatment-resistant depression: An alternative to KetamineShigeyuki Chaki, Japan

Neurochemical and behavioral effects of vagal nerve stimulationalan frazer, USa

S-17 eSymposium 15:00 – 17:00

Topic: Schizophrenia (a) Track: Translational

novel glutamatergic treatment approaches for schizophre-nia: Pharmacology, imaging and clinical trialsChair: Gerhard Gründer, Germany Co-chair: Dean F. Wong, USA

Challenges for novel treatment approaches in schizophreniaGerhard Gründer, Germany

The pharmacological basis for novel glutamatergic treat-mentsDaniel C. Javitt, USa

Characterization of novel glutamatergic treatments with PET imagingDean f. Wong, USa

Clinical results with novel glutamatergic treatmentsDaniel Umbricht, Switzerland

16


PRelIMInaRY SCIenTIfIC PRoGRaMMe | Tuesday, 24 June 2014

S-18 eSymposium 15:00 – 17:00

breakthroughs in psychopharmacology for prevention and treatment of PTSDChair: Eric Vermetten, The Netherlands Co-chair: Joseph Zohar, Israel

Three decades of research in circuits and receptor systems in PTSDeric Vermetten, The netherlands

New insights into secondary prevention in PTSDJoseph Zohar, Israel

Update on the use of alpha-1 adrenoreceptor antagonists for PTSDMurray Raskind, USa

Does the endocannabinoid system provide a new avenue for treatment development in PTSD?alexander neumeister, USa

S-19 eSymposium 15:00 – 17:00

Topic: biomarkers (including pharmacogenomics and brain imaging) for diagnosis and treatment response (C) Track: Translational

The psychopharmacology of aggression: from biomarkers to therapeuticsChair: Gabriella Gobbi, Canada Co-chair: Klaus-Peter Lesch, The Netherlands

Genetic determinants in aggressionKlaus-Peter lesch, The netherlands

Biomarkers in aggressive behaviorStefano Comai, Italy

Mood stabilizers in aggression: Basic and clinical researchGabriella Gobbi, Canada

Atypical antipsychotic in aggression: An updateleslie Citrome, Canada


DSM5 will be the death of psychopharmacology


Treatment of aDHD across the lifespan


Translating schizophrenia to animal models: What works and what doesn’t

S-20 eSymposium 15:00 – 17:00

Topic: Depression (a) Track: basic

Remodeling synaptic connections in the patho physiology and treatment of depressionChair: Ronald Duman, USA Co-chair: Eero Castren, Finland

Epigenetic regulation of synaptic remodeling in stress disordersScott Russo, USa

Cell genesis and dendritic plasticity: A neuroplastic pas de deux in the onset and remission from depressionnuno Sousa, Portugal

Antidepressant treatment reactivates developmental-like window of neuroplasticyeero Castren, finland

Synaptic homeostasis in the etiology and treatment of depressionRonald Duman, USa

17


Wednesday, 25 June 2014 | PRelIMInaRY SCIenTIfIC PRoGRaMMe


Clinical staging: Towards utility in diagnosis and clarity in neurobiological understanding in psychiatryPatrick D. McGorry, Australia

S-21 eSymposium 10:00 – 12:00

Topic: anxiety disorders (a) Track: Clinical

Personalized medicine in mood and anxiety disordersChair: Charles Nemeroff, USA Co-chair: Alan F. Schatzberg, USA

The preeminent role of early life trauma in vulnerability to mood and anxiety disorders: Neurobiological mecha-nisms of actionCharles nemeroff, USa

Advances in genomics and epigenetic biomarkers for vul-nerability and treatment response in mood and anxiety disorderselisabeth binder, Germany

The role of inflammation in the pathophysiology of de-pression: Treatment implicationsCarmine Pariante, United Kingdom

The contribution of HPA axis alterations in defining sub-types in depression: Genetic, endocrine and treatment studiesalan f. Schatzberg, USa

S-22 eSymposium 10:00 – 12:00

Topic: Schizophrenia (a) Track: Clinical

Is schizophrenia a progressive disease?Chair: Robert Zipursky, Canada Co-chair: Robin Murray, United Kingdom

Early course of cognitive impairment in schizophrenia: Effects and influenceseileen Joyce, United Kingdom

Schizophrenia is not progressive: The clinical evidenceRobin Murray, United Kingdom

Stress, drugs and inflammation: Understanding brain changes in psychosisChris Pantelis, australia

Expecting recovery not progression in schizophreniaRobert Zipursky, Canada

S-23 eSymposium 10:00 – 12:00


Psychiatric disorders, 24-hour circadian rhythms: Clock genes and new treatment implicationsChair: William Bunney, USA Co-chair: Joseph Takahashi, USA

Clock genes in control and major depressive disorder brain tissue: Possible mode of action of the rapid-acting antidepressant low-dose KetamineWilliam bunney, USa

Clock gene expression in bipolar disorder and schizo-phrenia: An effect of chronic stress on molecular rhyth-micityGabriella lundkvist, Sweden

Effects of clock gene variants and chronotherapeutics on hopelessness and suicidality in drug-resistant bipolar depressionfrancesco benedetti, Italy

Circadian transcriptional network in mammalsJoseph Takahashi, USa

S-24 eSymposium 10:00 – 12:00

Topic: Psychoneuroimmunology and neuroinflammation (C) Track: Translational

Gut microbiota and brain function: Relevance to psychiatric disordersChair: John Cryan, Ireland Co-chair: Mark Lyte, USA

The gut microbiota and neuroendocrine functionMark lyte, USa

Gut-brain axis: How the microbiome influences anxiety and depressionJane foster, Canada

Probiotics as regulators of brain and behaviorJohn Cryan, Ireland

Imaging the brain-gut-microbiome axis in humansemeran Mayer, USa


Personalized medicine: fact or fantasy?

18


PRelIMInaRY SCIenTIfIC PRoGRaMMe | Wednesday, 25 June 2014

W-9 eScientific Workshop 10:00 – 11:30

Pathways to CnS drug discoverySpeakers: Anthony Phillips, Canada Moussa Youdim, Israel Peter H. Andersen, Denmark

S-25 eSymposium 10:00 – 12:00

Topic: Pain (a) Track: basic

The expanding roles of microglia in chronic pain: Implica-tions for therapyChair: Michael Salter, Canada Co-chair: Yves De Koninck, Canada

Gene regulation in microglia in neuropathic painKazuhide Inoue, Japan

Microglia-neuron signaling mediates chronic pain-induced alterations in reward pathwaysCatherine Cahill, USa

The P2X4+ state of microglia is critical for neuropathic painMichael Salter, Canada

Microglia-mediated disruption of neuronal Cl-homeosta-sis mediates morphine hyperalgesiaYves De Koninck, Canada


optical deconstruction of fully-assembled biological systemsKarl Deisseroth, USA

S-26 eSymposium 15:00 – 17:00


Depression in pregnancy and postpartum: a treatment dilemma?Chair: John Kelly, Ireland Co-chair: Marie-Christine Pardon, United Kingdom

Antidepressant treatment in a model of post-partum de-pression age-dependently alter offspring’s CNS develop-mentMarie-Christine Pardon, United Kingdom

Maternal antidepressant exposure and CNS development in the rat offspringJohn Kelly, Ireland

What are the molecular and psychological mechanisms underlying the impact of maternal depression and anti-depressant use on the offspring?Carmine Pariante, United Kingdom

Impact of in utero exposure to antidepressants on the foetusMargareta Reis, Sweden

S-27 eSymposium 15:00 – 17:00

Topic: Clinical Investigator, national funding agency, Public-Private Partnership initiated clinical trials in the development of novel and effective CnS drugs and stimulation devices (C) Track: Clinical

a new nomenclature proposal for psychotropic drugsChair: Stephen Stahl, USA Co-chair: Joseph Zohar, Israel

AntidepressantsDavid nutt, United Kingdom

Anxiolytics and hypnoticsShigeto Yamawaki, Japan

AntipsychoticsStephen Stahl, USa

Results of the nomenclature surveys among more than 1.000 practicing psychiatrists Joseph Zohar, Israel

S-28 eSymposium 15:00 – 17:00

Depression (a) Track: Translational

Serotonin, stress and depression: Genetic and epigenetic factorsChair: Paul Albert, Canada Co-chair: Ramin V. Parsey, USA

Genetic mechanisms for longterm alterations in serotonin in depressionPaul albert, Canada

Increased serotonin-1A autoreceptor levels as trait of major depression and treatment resistanceRamin V. Parsey, USa

Steps and depression: A vicious cycle?Cathérine belzung, france

Genetic and epigenetic alterations in serotonin-regulating genes and depressionlinda booij, Canada

19

29th CInP WoRlD ConGReSS 2014

Wednesday, 25 June 2014 | PRelIMInaRY SCIenTIfIC PRoGRaMMe

S-29 eSymposium 15:00 – 17:00

Topic: biomarkers (including pharmacogenomics and brain imaging) for diagnosis and treatment response (C)Track: Translational

Clinically useful biomarkers in psychiatry: The promise and problemChair: Chad Bousman, AustraliaCo-chair: Brian Dean, Australia

Progress toward clinically useful biomarkers in psy chiatrybrian Dean, australia

Biomarkers for psychosis onset: Promising candidates from the genomeChad bousman, australia

Measuring oxidative damage to cortical white matter in blood samples from patients with mood disorders: Evolu-tion of biomarkers in psychiatryTrevor Young, Canada

Biomarkers for psychiatric disorders: Expectations and problems from a clinical point of viewHans-Jürgen Möller, Germany


antidepressants act to induce neurogenesis in the adult brain

Capilano Suspension bridge – Tourism Vancouver

W-10 eScientifi c Workshop 15:00 – 16:30

opto-genectics

S-30 eSymposium 15:00 – 17:00

Topic: neurodegenerative disorders: Parkinson, alzheimer, Huntington, fronto-Temporal Dementia, Vascular Dementia (a)Track: Translational

brain-Derived neurotrophic factor (bDnf) and synaptic plasticity as a drug target for cognitive dysfunction in CnS disordersChair: Pradeep Nathan, United KingdomCo-chair: Liliana Minichiello, United Kingdom

Molecular and cellular mechanisms of synaptic plasticity: Role of BDNFliliana Minichiello, United Kingdom

BDNF and the dimensions of memoryPedro bekinschtein, argentinia

Effect of BDNF polymorphism on markers of synaptic activity and cognition in healthy subjectsPradeep nathan, United Kingdom

BDNF and markers of disease progression in Alzheimer’s disease: Findings from the Australian Imaging Biomark-ers & Lifestyle Flagship Study of AgeingPaul Maruff, australia

20


PRelIMInaRY SCIenTIfIC PRoGRaMMe | Thursday, 26 June 2014

S-31 eSymposium 09:00 – 11:00


Polypharmacy in psychotic and affective disorders: Co-medication with antipsychotic and antidepressant drugsChair: Hans-Jürgen Möller, Germany Co-chair: Barbara J. Sahakian, United Kingdom

Treatment of negative vs. other symptoms in schizophreniaHans-Jürgen Möller, Germany

Concomitant antidepressant and antipsychotic medication in schizophrenia and depression – mechanisms of actionTorgny Svensson, Sweden

The role of atypical antipsychotics as add-on medication in major depressionSiegfried Kasper, austria

Current evidence for treatment of cognitive dysfunction in depressionbarbara J. Sahakian, United Kingdom

S-32 eSymposium 09:00 – 11:00


new insights into the role of nMDa receptors in cognition and psychosisChair: Andrew Holmes, USA Co-chair: Stan Floresco, Canada

NMDA-GluN2B receptors govern corticostriatal learning and cognitive flexibilityandrew Holmes, USa

NMDA receptor-associated proteins, cognition, and neu-ropsychiatric disorders – translation between mouse and humanTim bussey, United Kingdom

NMDA receptors and behavioural flexibility: For when things aren’t the way they used 2BStan floresco, Canada

NMDA receptors mediate the persistent firing of dorso-lateral prefrontal cortical circuits underlying mental rep-resentationamy arnsten, USa

S-33 eSymposium 09:00 – 11:00

Topic: biomarkers (including pharmacogenomics and brain imaging) for diagnosis and treatment response (C) Track: Translational

Converting biological findings into routine clinical tests – Psychiatry’s next big challengeChair: Shitij Kapur, United Kingdom Co-chair: Roy Perlis, USA

Converting biological psychiatry into clinical tests – why has it been so hard and what to do about itShitij Kapur, United Kingdom

Clinical relevance – what does it mean when developing clinical testsRudolf Uher, Canada

From pharmacogenetics to clinical testsRoy Perlis, USa

Pharmacogenetic tests for psychotropics – a journey from bench to bedsideTony altar, USa

S-34 eSymposium 09:00 – 11:00

novel therapeuticsChair: Elias Eriksson, Sweden

S-35 eSymposium 09:00 – 11:00


adult aDHD and obesity: neurotransmitter imaging and pharmacotherapies targeting impulsivity Chair: Ulrich Muller, United Kingdom Co-chair: Catharine Winstanley, Canada

Preclinical models of impulsivity: Pharmacological and dietary manipulationsCatharine Winstanley, Canada

Imaging of the dopaminergic system in ADHD, binge eating and obesityGene-Jack Wang, USa

Imaging of the noradrenergic system in adults with obesity and ADHDSwen Hesse, Germany

Pharmacological treatment of ADHD in adults: Implica-tions for binge eating and obesityUlrich Muller, United Kingdom

21


Thursday, 26 June 2014 | PRelIMInaRY SCIenTIfIC PRoGRaMMe


The abC’s and CpGs of epigenetics


The impact of neuroimaging on understanding psychiatric disorders

S-36 eSymposium 09:00 – 11:00

Topic: neurodegenerative disorders: Parkinson, alzheimer, Huntington, fronto-Temporal Dementia, Vascular Dementia (a) Track: basic

Synaptic plasticity and neurodegenerationChair: Graham Collingridge, United Kingdom Co-chair: Yu Tian Wang, Canada

Synaptic plasticity and AD: Roles of GSK-3beta and the JAK/STAT pathwayGraham Collingridge, United Kingdom

The NMDA receptor as a mediator of cell survival and cell deathYu Tian Wang, Canada

Caspases in synaptic plasticity and ADMorgan Sheng, USa

The role of receptor tyrosine kinases and cyclin-dependent kinase 5 in synaptic plasticity and ADnancy Y. Ip, Hong Kong

PL-07 eCINP/CCNP Lecture 11:15 – 12:00

Interactions between neurotransmitters: The key to remis-sion for depressionPierre Blier, Canada

22


Call foR PoSTeR abSTRaCTS

Submission of Poster abstractsParticipants are invited to submit abstracts for poster pre-sentations. These should give a brief description of the title and topic.

all abstracts will be assessed by members of the Interna-tional Scientific Programme Committee. The assessors will judge the abstracts according to the relevance to CInP, standard of english, objectivity of statement, description of what was done, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, po-tential clinical value, originality of work and overall impres-sion. all accepted abstracts will be published in the online International Journal of neuropsychopharmacology (IJnP) and online on the congress website: www.cinp2014.com

Please visit the congress website www.cinp2014.com for detailed instructions regarding the electronic submission of abstracts. The deadline for poster submissions is: 5 February 2014

Guidelines for Submission

l abstracts must be submitted in english.

l The successful participant is committed to present their posters at the designated time slot allocated to them by the International Scientific Programme Committee.

l Changes in authorship should be communicated to the International Scientific Programme Committee in order to ensure correct appearance in the printed programme until 15 April 2014: [email protected]

l If the original presenting author is unable to present, one of the co-authors should take over this responsibility.

l When participants are submitting a poster abstract, they must submit a completed registration form and payment of the correct registration fee. both must be received by the congress and exhibition office CPo HanSeR SeRVICe no later than 5 February 2014.

l If the poster is not accepted the delegate will have the right to recieve a full registration refund.

We encourage submitting authors to register via the online registration system along with the abstract submission. The acceptance of abstracts by the International Scientific Programme Committee does not imply any financial assis-tance or fee reduction.

notification of acceptance or rejection by the International Scientific Programme Committee will be emailed to the presenting author. Detailed information, guidelines and re commendations for poster presentation, as well as time allocation, date, hour, and venue will be sent in due time to registered presenting authors.

Guidelines for Preparation of abstractsPlease choose a title that clearly indicates the content of the contribution. Please avoid abbreviations in the title. abbreviations may be used in the text if they are defined when used first. a maximum of 300 words is allowed. The author’s name (full first name, family name) and place of work (institution, city, country) should be indicated. De-grees, titles, street addresses and acknowledgements of support should be omitted, however.

To provide maximum information in the abstract please

l state the specific objective of the study

l state the methods used, if pertinent

l summarize the results obtained

l state the conclusions reached

Please ensure that the abstract does not contain spelling, grammar or scientific errors, as it will be reproduced ex-actly as submitted.Please submit a poster which is relevant to the conference topic, see page 23.

Poster SessionsPoster sessions will be held from Monday, 23 June to Wednesday, 25 June 2014. These sessions offer an interac-tive forum for the exchange of information and a means to communicate ideas, research, and programmes. Poster au-thors must attend these sessions to give feedback to con-ference attendees who stop by to ask questions. at this congress, posters will be grouped by topics for the conve-nience of those attending the sessions.

Poster awardsClinical, translational, and basic neuroscience research awards are given. Those presenting the best posters receive a certificate. These awards serve to encourage young scien-tists (under 35) who are actively involved in clinical and pre-clinical research. The final selection of Poster awards will be made on the basis of the study’s scientific excellence.

application for Poster awardsTo be eligible for a poster award, the applicant (scientists under 35) must check the applicable box on the online poster submission form at: www.cinp2014.com.

23


TopicsThe CInP International Scientific Programme Committee has selected symposia proposals that link the latest pre-clinical deve lopments with clinical research on a given topic. CInP encourages the integration of psychiatric and neurological perspectives at its congresses. Through the free and open exchange of ideas, CInP supports a strong focus on new approaches to the development and assess-ment of CnS pharmaceuticals by researchers working in both academia and industry.

for posters the following topics are to be selected:

Theme aDiseases of the Nervous System. Current preclinical and clinical perspectivesSub-topics

l addictive disorders

l anxiety disorders

l bipolar disorder

l Depression

l eating disorders

l Schizophrenia

l Post-traumatic stress disorder

l neurodegenerative disorders, including Parkinson’s disease; alzheimer’s disease; Huntington’s disease; fronto-temporal dementia; vascular dementia

l epilepsy

l Traumatic brain injury and mental health

l Pain

l Sleep disorders

Theme bDiseases of the Nervous System (Techniques). Current preclinical and clinical perspectivesSub-topics

l neuroimaging

l neuropathology / post mortem-studies

l neurophysiology; from ion channels to cortical eeG

Theme CInnovation in Therapeutic Development and Assessment of Drugs and Stimulation devicesSub-topics

l biomarkers (including pharmacogenomics and brain imaging) for diagnosis and treatment response

l Clinical Investigator, national funding agency, Public-Private Partnership initiated clinical trials in the development of novel and effective CnS drugs and stimulation devices

l Use of traditional medicine to guide novel CnS drug development

l Psychoneuroimmunology and neuroinflammation

Theme DDevelopmental Perspectives on Neuropsycho -pharma cology Sub-topics

l autism spectrum disorders

l attention deficit disorders

l foetal-alcohol spectrum disorders

l anxiety disorders and phobias

Theme eIntegrative Approaches to NeuropsychopharmacologySub-topics

l ethics in neuropsychopharmacology

l Gender and mental health

l History of neuropsychopharmacology

l Pharmacoeconomics

l Transcultural psychopharmacology

Theme fOthers

CMe accreditationThe 29th World Congress on neuropsychopharmacology 2014 is in the process of seeking approval from the euro-pean accreditation Council for Continuing Medical educa-tion in brussels (eaCCMe) to provide Continuing Medical education (CMe) credits to physicians for attendance at the scientific sessions. The eaCCMe is an institution of the eu-ropean Union of Medical Specialists (UeMS).

Through an agreement between the european Union of Medical Specialists and the american Medical association, physicians may convert eaCCMe credits to an equivalent number of aMa PRa Category 1 Credits™. Information on the process to convert eaCCMe credit to aMa credit can be found at www.ama-assn.org/go/internationalcme.

ToPICS / CMe aCCReDITaTIon

24


lilly neuroscience basic Research awardThe lilly neuroscience basic Research award is given to a scientist in recognition of an outstanding contribution to psychopharmacology and will be presented at the 29th CInP World Congress in Vancouver, Canada. The recipient of the 2014 award will be chosen by an international scien-tific jury by March 2014. This award consists of a monetary award of USD 10.000, an engraved plaque, paid registra-tion fees for the congress, round trip economy air travel, and up to four nights’ accommodation at a congress hotel.This activity is supported by a contribution from lilly.

lilly neuroscience Clinical Research awardThe lilly neuroscience Clinical Research award is given to a scientist in recognition of an outstanding contribution to psychopharmacology and will be presented at the 29th CInP World Congress in Vancouver, Canada. The recipient of the 2014 award will be chosen by an international scientific jury by March 2014. This award consists of a monetary award of USD 10.000, an engraved plaque, paid registration fees for the congress, round trip economy air travel, and up to four nights’ accommodation at a congress hotel. This activity is supported by a contribution from lilly.

Max Hamilton Memorial PrizeMax Hamilton, M.D., f.R.C.P., f.R.C. Psych., D.P.M. (1912 – 1988) is best known for his assessment of depressive ill-ness through psychometrics. The Hamilton rating scale for depression is widely used throughout the world, and his 1960 paper on the problem of measuring the severity of depression is probably the most cited medical publication in the second half of the twentieth century. The recipient of the 2014 award will be chosen by an international scientific jury by March 2014. This prize consists of a monetary award of USD 10.000 and an engraved plaque, to be presented at the 29th CInP World Congress in Vancouver, Canada. This award is supported by astraZeneca.

CInP Pioneers in Psychopharmacology awardThe award is given at each CInP World Congress to three individuals to honour those who have made major contri-butions to the field as it has developed. The contributions may be in research, clinical, or administrative areas but must be internationally recognised as significant to the growth of the field. Pioneer awardees receive round trip air travel and accommodation at the 29th CInP World Con-gress in Vancouver, Canada, an engraved plaque, paid re-gistration fees and appropriate recognition at the meeting.

Rafaelsen Young Investigators awardIn 1986 ole Rafaelsen and William bunney were instru-mental in establishing a CInP programme supporting the attendance of young scientists at the 15th CInP Congress in 1986. That programme was posthumously named the Rafaelsen fellowship award to honour Dr. Rafaelsen, who died in 1987. The recipients of the 29th Congress Rafa-elsen awards will be chosen by an international scientific jury by March 2014. a number of awardees will be selected and presented with awards consisting of round trip econo-my air travel, up to four nights’ accommodation, a certifi-cate, a cash stipend including an element for ground trans-portation and waived registration fees at the 29th CInP World Congress in Vancouver, Canada.

CInP ethics Prize in PsychopharmacologyThe CInP ethics Prize in Psychopharmacology recognizes achievements in research in ethics in psychopharmacology, in promotion of public awareness of ethics in psychophar-macology and contributions to the world wide solution of problems in ethical practice of psychopharmacology. The recipient of this award will be chosen by the ethics Prize Committee, an international committee of experts in the field in the beginning of March 2014. applicants must be nominated by a CInP member and include a CV and one to three page statement of the justification of the nomination. The successful applicant will receive complimentary regis-tration and up to four nights’ accommodation at the con-gress hotel.

How to applynominations for all the awards must be submitted by

10 January 2014

and sent to the CInP Central office. Please complete and re-turn the appropriate form to apply for the awards. Judges will make their decision on all applications by March 2014. Please encourage your colleagues to apply for these awards.

further details of the CInP awards can be found on the respective application forms in this brochure, please see from page 31.

CInP aWaRDS

25


CInP award History

Previous Lilly Neuroscience Clinical Research Awardees2010 Paul J. Harrison

University of oxford, UK

2008 Rainer Rupprecht University of Munich, Germany

2006 Michael Davidson Sheba Medical Center, Israel

2004 Dennis S. Charney national Institute of Mental Health, USa

2002 Jeffrey lieberman University of north Carolina at Chapel Hill, USa

Previous Lilly Neuroscience Basic Research Awardees2010 Pierre blier

University of ottawa, Canada

2008 anthony Grace University of Pittsburgh, USa

2006 Ronald Duman Yale University School of Medicine, USa

2004 John l. Waddington Royal College of Surgeons, Ireland

2002 Robert Malenka Stanford University, USa & eric nestler, Univ. of Texas Southwestern Medical Center, USa

Previous Max Hamilton Awardees2012 elisabeth binder

Max-Planck Institute of Psychiatry, Germany

2010 Jean-Martin beaulieu Université laval, Canada

2008 George Papakostas Harvard Medical School, USa

2006 alexander neumeister Yale University School of Medicine, USa

2004 Sarah H. lisanby new York State Psychiatric Institute at Columbia University, USa

2002 Dan Stein MRC Research Unit, South africa

Previous Pioneers in Psychopharmacology Awardees2012 William bunney, USa Karl Rickels, USa Moussa l. Youdim, Israel

2010 Per bech, Denmark Salomon langer, Israel Teruo okuma, Japan

Previous Ethics Prize in Psychopharmacology Awardees2010 Dan Stein, South africa

Previous Rafaelsen Young Investigator Travel Awardees2012 e eleonore beurel

UM Miller School of Medicine, USa e lior Greenbaum

Hadassah-Hebrew University Medical Center, Israel

e Samia lourenco Joca University of Sao Paulo, brazil

e anurag Kuhad, Panjab University, India

e Kim Kuypers Maastricht University, faculty of Psychology and neuroscience, The netherlands

e Ciara McCabe Warneford Hospital, UK

e Clinton b. McCracken University of Calgary, Canada

e Kazutaka ohi osaka University Graduate School of Medicine, Japan

e Christoph J. Spindelegger Medical University of Vienna, austria

e elizabeth Tunbridge Warneford Hospital, UK

2010 e Dara Cannon, Ireland e bonginkosi Chiliza, South africa e Chris Martin Dodds, UK e benicio frey, Canada e Se Hyun Kim, Republic of Korea e eduard Maron, estonia e Keri Martinowich, USa e Gretchen neigh, USa e Kalmane Sridhara Pavitra, India e li Yang, China

CInP aWaRDS

26


ConGReSS ReGISTRaTIon

Please register online for CInP 2014 at www.cinp2014.com.

Registration fee for members, non-members, young scien-tists, delegates from developing countries and students includes:a admission to all scientific sessionsa admission to opening Ceremony and Welcome Receptiona admission to poster exhibition and technical exhibitiona Congress materials, such as final Programme

Registration fee for accompanying persons includes:a admission to opening Ceremony and Welcome Reception a Tour “Photographic Tour of Vancouver”, 3 hrs on Sun-

day or Monday

Registration ConditionsThe binding booking, payment and cancellation conditions of the CInP congress registrations are published on the congress website. Please refer to www.cinp2014.com

Congress office Please register online for CInP 2014. You may also use the enclosed registration form. Should you require additional registration forms, please copy this form. Please return the completed registration form as soon as possible in order to benefit from the lower registration fee by mail or by fax to:

office HamburgHanser & Co GmbHPo box 12 2122882 barsbüttel, GermanyPhone: +49 – 40 – 670 88 20fax: +49 – 40 – 670 32 83email: [email protected]

ConfirmationUpon receipt of the registration and the corresponding payment, the congress office will send a confirmation to the participant which also serves as an invoice. Please present this confirmation of registration at the congress counter when picking up your congress material.

Who is WhoTheir consent provided, delegates will be given the possi-bility to have their name, institution, city and country listed in the list of participants published on the internet. Upon request a direct link to the homepage of the participant or his / her institution can be installed.

PaymentWhen registering for the CInP World Congress 2014 please arrange payment of the registration fee. all pay-ments must be made in eUR. We recommend credit card payment. all bank collection fees are in the sole responsi-bility of the registrant.

eCredit card (aMeX, eurocard / Mastercard, VISa)ebank transfer to the congress bank account:

Hanser & Co w/CInP 2014 ZbHSH nordbank aGbIC: HSH nDe HHIban: De38 2105 0000 1001 2457 83

Cancellation PolicyIn case of cancellation, please notify the congress office in writing only. a full refund (minus an administrative charge of eUR 100) will be given for cancellations received until 5 feb-ruary 2014. after 5 february 2014, no refunds will be given.

Registration and payment received – fees valid since 2010 –

until 5 February 2014 until 20 May 2014 after 20 May 2014

CInP Member eUR 500 eUR 600 eUR 700

non-Member eUR 700 eUR 800 eUR 900

Young Scientist * eUR 300 eUR 350 eUR 400

Delegate from Developing Country ** eUR 200 eUR 220 eUR 240

Student *** eUR 110 eUR 130 eUR 150

accompanying Persons eUR 90 eUR 90 eUR 90

* applicants must be under 35 years of age and a copy of passport or other government-issued ID must be forwarded along with the registration.

** Developing Countries: a limited number of developing countries registrations are available. To be eligible, you must reside in one of the countries, as classified by the World bank. The valid list is published at www.cinp2014.com.

*** Students aged less than 35 years who are studying for a degree including first degrees, PhD or MD but who have not yet obtained their degree. They must supply a letter from their supervisor or laboratory head to support their application for this reduced fee.

27


Developing Countries list a limited number of developing countries registrations are available. To be eligible, you must reside in one of the fol-lowing countries, as classified by the World bank. Compa-nies inviting delegates cannot apply for these fees.

The valid list is published at www.cinp2014.com. Sponsoring companies inviting delegates from developing countries shall register their delegates for the full registration fee for mem-bers or non-members. The use of the congress fee for devel-oping countries cannot be booked by industry companies.

ConGReSS ReGISTRaTIon

afghanistan albaniaangolaarmeniaazerbaijanbangladeshbelizebeninbhutanboliviaburkina fasoCambodiaCameroonCape VerdeCentral african RepublicChadChinaComorosCongo, Dem. Republic. Congo, RepublicCote d’Ivoire Djiboutiecuadoregypt. arab Rep. el SalvadoreritreaethiopiaGambiaGeorgiGhanaGuatemalaGuineaGuinea-bissau

GuyanaHaiti HondurasIndiaIndonesiaIran, Islamic Republic IraqJordanKenyaKiribatiKorea, Dem. Rep. Kosovo Kyrgyz Republiclao PDR lesotholiberiaMadagascar Malawi Maldives Mali Marshall Islands Mauritania Micronesia, fed. Sts. Moldova Mongolia Morocco Mozambique Myanmar nepal nicaragua niger nigeria Pakistan

Papua new GuineaParaguay Philippines Rwanda Samoa São Tomé and Principe Senegal Sierra leone Solomon Islands Somalia Sri lanka Sudan Swaziland Syrian arab Republic Tajikistan Tanzania Thailand Timor-leste Togo Tonga Tunisia Turkmenistan Uganda Ukraine Uzbekistan Vanuatu Vietnam West bank and Gaza Yemen, Republic. Zambia Zimbabwe

28


Congress VenueVancouver Convention Centreeast Wing1055 Canada PlaceVancouver, bC, V6C 0C3, Canada

Congress Registration DeskThe congress counter will be located in the entrance hall of the east Wing of the Vancouver Convention Centre.

Preliminary opening HoursSunday, 22 June 2014 e14:00 – 18:00Monday, 23 June 2014 e07:30 – 18:00Tuesday, 24 June 2014 e07:30 – 18:00Wednesday, 25 June 2014 e07:30 – 18:00Thursday, 26 June 2014 e08:00 – 13:00

Congress and exhibition / Sponsor office

office HamburgHanser & Co GmbH Zum ehrenhain 34 22885 barsbüttel, GermanyPhone: +49 – 40 – 670 882-0fax: +49 – 40 – 670 32 83 email: [email protected]

Poster exhibitionPosters will be displayed from Monday, 23 June until Thursday, 26 June in the east exhibition Hall a of the Van-couver Convention Centre. The posters will be changed daily and are on display during the opening hours of the technical exhibition. Information regarding poster format, set-up and dismantling will be sent to the authors along with their notification of acceptance.

Technical exhibitionThe 29th CInP World Congress will be accompanied by a major technical exhibition taking place in the east exhibi-tion Hall a. Potential exhibitors can request an exhibition / sponsoring brochure from the Congress and exhibition / sponsor office, CPo HanSeR SeRVICe.email: [email protected]

Preliminary opening HoursMonday, 23 June 2014 e09:00 – 17:00Tuesday, 24 June 2014 e09:00 – 17:00Wednesday, 25 June 2014 e09:00 – 17:00

GeneRal InfoRMaTIon

Congress Information System: Co ConGReSS onlIne®

for the 29th CInP World Congress 2014, the web based Congress Information System Co ConGReSS onlIne® has been installed: www.cinp2014.com

Prior to the congress Co ConGReSS onlIne® will pro-vide information on:

ePreparation of the congresselist of topicseCall for abstractsefaculty ePreliminary scientific programmeeaccepted abstractseSatellite symposia elist of participants (Who is Who)elist of exhibitorseSupporting programmeelevel sponsors and general sponsorseCongress venueeCity of VancouvereHotel accommodationeTravel to VancouvereSpecial newsePrivate Mailbox

Congress Websitefurther and updated information will be available on the internet at www.cinp2014.com Registration, hotel reservation and submission of abstracts are available online.

CInP 2014 Congress app Get the 2014 CInP Congress app for your smartphone and experience the congress at your fingertips! Stop carrying around piles of paper and quickly find your way through the most up-to-date congress schedule. Just take the congress with you, wherever and whenever you want ! The app will be completely free and provides iPhone/iPad and android users at CInP 2014 in Vancouver with on-the-go access to the schedule and vital information around the congress. e available for download 2 weeks prior to the CInP 2014

World Congresse Powered by GlobIT’s critically acclaimed ConGReSS

MobIle software

Congress languageThe official language of the 29th CInP World Congress is english.

29


final Programme and abstractsThe final Programme and abstracts will be published on the Internet at Co ConGReSS onlIne® prior to the con-gress. Participants will receive a copy of the final pro-gramme with their congress material. abstracts will be published in the official online journal of CInP, the Interna-tional Journal of neuropsychopharmacology.

letter of InvitationThe congress organisers will be pleased to send a formal letter of invitation to registered delegates requesting an in-vitation letter for visa purposes. It is understood that such an invitation is intended to help potential delegates to raise funds or to obtain a visa. This does not imply a commitment from the congress to provide any financial support. letters of invitation may be requested from the congress office not later than 15 May 2014. The letters will be sent by email or upon request by postal mail. In case an express delivery is needed, the delegate shall order a courier at his / her own expense. Please email [email protected] for your official letter of invitation.

VisaMost travelers will need a passport valid for at least 90 days following your departure date from Canada. Visa regula-tions for Canada vary according to the country of origin. Please address enquiries about entry requirements to your travel agent or local Canadian consulate. for further infor-mation please visit www.cic.gc.ca

official Italian agency The appointed agency to collect all applications from the pharmaceutical companies and file them with the aIfa (Italian drug agency) is:

aIM Group International – aIM education S.r.l.Via G. Ripamonti, 129, 20141 Milan / ItalyPhone: +39 02 56601.1fax: +39 02-70048585email: [email protected]

GeneRal InfoRMaTIon

Housing and Tours for the 29th CInP World Congress, the hotel accommodation and tours for the participants will be arranged by our on-site partner company ICS.

Local AgencyInternational Conference Services ltd.2101 – 1177 West Hastings StreetVancouver, bC, Canada V6e 2K3Phone: +1 604 681 2153 Contact: Tina lobo-Hardick email: [email protected]

Please book your hotel and tours online with ICS. all hotels are in walking distance to the congress venue and are avai lable online via congress website: www.cinp2014.com.

ICS – our Servicesas the official housing bureau for CInP we have secured a variety of hotels that range from the truly luxurious to more conservative accommodations. Whether in the heart of downtown, or situated in one of the wonderful communities of Greater Vancouver, there is a hotel for every taste, budget and need. Depending on the property you select, your hotel stay will include a wide range of amenities, exclusive to CInP delegates!

our hotel partners offer everything you need to feel right at home, from complimentary breakfast, to Wifi access, bottled water, and even bedroom slippers at some prop-erties! others offer in-house perks you will not find at home, such as valet parking, dry cleaning, health club passes and full business centres on-site.

Vancouver’s diverse accommodation options range from traditional and elegant to trendy and modern, all with its fantastic night life and one-of-a-kind dining experiences just a stone’s throw away. Where else can you choose between an extraordinary mountain view and a breath-taking ocean view, while being in the heart of downtown?

for CInP delegates, we have secured numerous proper-ties from which you can choose with a variety of rates ranging from as low as $134 for a basic room in a prime location, to $489 for two bedroom suites if you are look-ing for an indulgent getaway experience. online hotel booking is now open, visit the congress website:www.cinp2014.com / accommodation-tours.html to plan your stay today!

30


GeneRal InfoRMaTIon

about Vancouverlocated on the west coast of the north american mainland, Vancouver is located between the Pacific ocean and the Rocky Mountains. The City of Vancouver occupies 2,930 square kilometres on and around the fraser River delta and has a population of 603,000, estimated in the 2011 census. as well as hosting the successful 2010 olympic and Para-lympic winter games Vancouver has also become an in-creasingly important player in forest product and mining, software development, biotechnology, aerospace, video game development, animation and film production.

The natural surroundings of Vancouver and british Colum-bia offer a wide range of outdoor activities such as sailing, climbing, skiing and whale watching. The city is also home to several large beaches and over 3210 acres of park. for indoor pursuits, Vancouver offers the congress delegates the opportunity to engage with the sciences and arts at one of its many art galleries, theatres and at Science World, a not-for-profit organisation dedicated to engaging and inspiring british Columbians in the fields of science and technology. among its many initiatives Vancouver City Council manage a series of programmes, awards and cel-ebrations that seek to recognise the city’s cultural diversi-ty. future projects include the goal of becoming the World’s greenest city in 2020. Many initiatives such as car-bon neutral buildings, new bike lanes and leading edge recycling programmes are already underway.

airport InformationVancouver International airport (IaTa: YVR, ICao: CYVR) is located on Sea Island in Richmond, british Columbia, Canada, about 12 km from downtown Vancouver. Vancou-ver International airport is well regarded as one of the most accessible airports in the world. In 2004, Vancouver International airport was awarded the Rick Hansen acces-sibility award, which recognizes facilities and communi-ties that improve the quality of life for people with mobility limitations.

Transport between the airport and the CityLocal Transportation The Vancouver Convention Center is in the Downtown City Center of Vancouver. It can be reached by several public transportation possibilities:

Translink provides city transit for tourists and residents seven days a week via buses through its transit system, SkyTrain. With the opening of the Canada line, travel be-tween the Waterfront Station and Vancouver International airport has been significantly reduced to 26 minutes per one-way trip. This allows for a more convenient trip for international travellers to and from downtown Vancouver.

Metro / Public Transportation Under the auspices of the South Coast british Columbia Transportation authority the Metro Vancouver operates a regional rapid mass transit network, known as Translink. It is responsible for all aspects of municipal transportation.Translink is introducing an electronic Compass Card to re-place existing monthly and daily passes, tickets and cash.a bus service operates throughout most of the region un-der a private subsidiary known as Coast Mountain bus Company. all buses are wheelchair-accessible. Vancouver is actively maintaining and upgrading its trolleybus fleet.Vancouver also offers a Seabus Service. It is a passenger-only ferry connecting downtown Vancouver and the City of north Vancouver across burrard Inlet. There are three fer-ries in the fleet.

TaxiVancouver taxi cabs are allowed to operate within the Van-couver area, including Vancouver International airport. Taxis can be called, hailed on the street or found at one of more than 50 official taxi ranks located around the city. The ranks can be found near the common tourist spots such as the art Gallery, the aquarium or the Science World TelUS.

bank and aTMbanks are open weekdays between 9:30am and 4:00pm. Many banks are closed on Saturday and Sunday, though some have limited services on a Saturday morning. Most shops and restaurants in Vancouver accept the common credit cards like Visacard, american express and Mastercard.

ClimateVancouver has a moderate oceanic climate with summer months that are typically dry, often resulting in moderate drought conditions in July and august. from June to au-gust daytime temperatures linger just above 20° Celsius / 70° fahrenheit. evenings, especially in the surrounding mountains, are a bit cooler.

CurrencyThe currency in Canada is the Canadian Dollar. exchange Rate: 1 eUR – 1,4042 Canadian Dollar (as of august 2013)

electricityThe electrical supply is 110 Volts and 60 Hertz. Canada uses the two-flat pin system.

Time ZoneCanada is divided into six time zones: newfoundland, at-lantic, eastern, Central, Mountain and Pacific. Vancouver is located in the Pacific time Zone: UTC−08:00 (PST).

The International College of NeuropsychopharmacologyThe lilly neuroscience basic Research award will be presented at the 29th CInP Congress in Vancouver, Canada. The recipient of the 2014 award will be chosen by an international scientific jury by March 2014. This award consists of a monetary award of $10,000 (USD); an engraved plaque, paid registration fees for the Congress; round trip economy air travel; and up to four nights’ accommodation at the Congress Hotel.

Previous Lilly Neuroscience Basic Research Awardees2010: Pierre blier, University of ottawa, Canada2008: anthony Grace, University of Pittsburgh, USa2006: Ronald Duman, Yale University School of Medicine, USa2004: John l. Waddington, Royal College of Surgeons, Ireland2002: Robert Malenka, Stanford University, USa & eric nestler, Univ. of Texas Southwestern Medical Center, USa

Guidelinese The lilly neuroscience basic Research award is given to a scientist in recognition of an outstanding

contribution to psychopharmacologye Candidates must be less than 55 years of age as of 1 January 2014e Candidates must be nominated by a member of the CInP. The nominee should be affiliated with a

Hospital, University, or Research Institutione The awardee must commit to attendance at the 2014 Congress for at least three full days

To submit a nomination, the following application materials must be submitted by email or by hard copy in English, by the 10 January 2014 deadline:

e a Curriculum Vitaee no more than five (5) published articles representing the work accomplishede a summary not exceeding four (4) double-spaced typed pages explaining the significance of the contributione a letter of nomination from a CInP membere This completed form

full name of nominee:

Present position:

address:

Tel: fax:

email: Date of birth:

I hereby confirm that my application is complete and that I subscribe to all regulations governing the lilly neuroscience basic Research award. You can submit your application by email, fax or post.

Current date: nominee’s Signature:

Please return completed applications to:Pierre blier, Chair, fellowship & awards Committeelilly neuroscience basic Research awardCInP Central officeGlenfinnan Suite, braeview House, 9/11 braeview Placeeast Kilbride, Glasgow, G74 3XHScotland, UK

Tel + 44 (0) 1355 244930fax + 44 (0) 1355 249959email: [email protected]

This application will be copied for submission or to distribute to others.

lIllY neURoSCIenCe baSIC ReSeaRCH aWaRD

The International College of NeuropsychopharmacologyThe lilly neuroscience Clinical Research award will be presented at the 29th CInP Congress in Vancouver, Canada. The recipient of the 2014 award will be chosen by an international scientific jury by March 2014. This award consists of a monetary award of $10,000 (USD); an engraved plaque; paid registration fees for the Congress; round trip economy air travel; and up to four nights’ accommodation at the Congress Hotel.

Previous Lilly Neuroscience Clinical Research Awardees2010: Paul J. Harrison, University of oxford, UK2008: Rainer Rupprecht, University of Munich, Germany2006: Michael Davidson, Sheba Medical Center, Israel2004: Dennis S. Charney, national Institute of Mental Health, USa.2002: Jeffrey lieberman, University of north Carolina at Chapel Hill, USa

Guidelinese The lilly neuroscience Clinical Research award is given to a scientist in recognition of an outstanding

contribution to psychopharmacology.e Candidates must be less than 55 years of age as of 1st January 2014.e Candidates must be nominated by a member of the CInP. The nominee should be affiliated with a

Hospital, University, or Research Institution.e The awardee must commit to attendance at the 2014 Congress for at least three full days.

To submit a nomination, the following application materials must be submitted by email or hard copyin English, by the 10 January 2014 deadline:

e a Curriculum Vitaee no more than five (5) published articles representing the work accomplishede a summary not exceeding four (4) double-spaced typed pages explaining the significance of the contributione a letter of nomination from a CInP membere This completed form


Present position:

address:

Tel: fax:


I hereby confirm that my application is complete and that I subscribe to all regulations governing the lilly neuroscience Clinical Research award. You can submit your application by email, fax or post.


Please return completed applications to:Pierre blier, Chair, fellowship & awards Committeelilly neuroscience Clinical Research awardCInP Central officeGlenfinnan Suite, braeview House, 9/11 braeview Placeeast Kilbride, Glasgow, G74 5XHScotland, UK

Tel: + 44 (0) 1355 244930 fax: + 44 (0) 1355 249959 email: [email protected]


lIllY neURoSCIenCe ClInICal ReSeaRCH aWaRD

MaX HaMIlTon MeMoRIal PRIZe

The International College of NeuropsychopharmacologyMax Hamilton, M.D., f.R.C.P., f.R.C.Psych., D.P.M. (1912-1988) is best known for his assessment of depressive illness through psychometrics. The Hamilton Rating Scale for Depression is widely used throughout the world, and his 1960 paper on the problem of measuring the severity of depression is probably the most cited medical publication in the sec-ond half of the twentieth century. The recipient of the 2014 award will be chosen by an international scientific jury by March 2014. This prize consists of a monetary award of $10,000 (USD) and an engraved plaque, to be presented at the 29th CInP Congress in Vancouver, Canada.

Previous Max Hamilton Awardees2012: elisabeth binder, Max-Planck Institute of Psychiatry, Germany2010: Jean-Martin beaulieu, Université laval, Canada2008: George Papakostas, Harvard Medical School, USa2006: alexander neumeister, Yale University School of Medicine, USa2004: Sarah H. lisanby, new York State Psychiatric, Institute at Columbia University, USa

Guidelinese The Max Hamilton Memorial Prize is given to a young scientist in recognition of an outstanding contribution

to psychopharmacology.e nominations can be made by any individual; nominees need not be members of the CInP,

but must be less than 41 years of age on 31 December 2014.e The contributions may be in clinical evaluation or services, in pre-clinical or clinical research, or any combination

of these.e The contributions may be empirical advances or a theoretical construct, based on a single discovery or a cumulative

body of work.e The awardee must commit to attendance at the 2014 Congress for at least three full days.


e This completed forme no more than 500 words summarizing the basis for nominatione an up-to-date curriculum vitae including a list of publications


Present position:

address:

Tel: fax:


I hereby confirm that my application is complete and that I subscribe to all regulations governing the Max Hamilton Memorial Prize. You can submit your application by email, fax or post.


Please return completed applications to:Pierre blier, Chair, fellowship & awards CommitteeMax Hamilton Memorial PrizeCInP Central office, Glenfinnan Suite, braeview House, 9/11 braeview Place, east Kilbride, Glasgow, G74 3XH, Scotland, UK

Tel: + 44 (0) 1355 244930 fax: + 44 (0) 1355 249959 email: [email protected] This application will be copied for submission or to distribute to others.

CInP PIoneeRS In PSYCHoPHaRMaColoGY aWaRD

The International College of NeuropsychopharmacologyThe award is given at each Congress to three individuals to honour those who have made major contributions to the field as it has developed. The contributions may be in research, clinical, or administrative areas but must be internationally recognized as significant to the growth of the field. Pioneer awardees receive round trip economy air travel and accom-modation at the 29th Congress in Vancouver, paid registration fees and appropriate recognition at the meeting.

Previous Pioneers 2012: William bunney (USa), Karl Rickels (USa), Moussa l. Youdim (Israel)2010: Per bech (Denmark), Salomon langer (Israel), Teruo okuma (Japan)2008: Jean-Pierre Changeux, (france), Samuel Gershon, (USa) and Hannah Steinberg, (UK)2006: leonard Cook, (USa), fridolin Sulser, (USa), Merton Sandler, (UK)2004: Hanns Hippius (Germany), alfred Pletscher (Switzerland) and Herman M. van Praag (The netherlands)2002: frank ayd, Jr. (USa), arvid Carlsson (Sweden) and Jonathan Cole (USa)

The executive Committee selects these individuals and is soliciting candidates from psychopharmacologists around the world. Send a letter by any mode to the President, anthony Phillips, c/o CInP Central office proposing any nomination and the reasons why this person should be considered for an award, with details of their principal contributions to psy-chopharmacology by 10 January 2014.

Please send your nominations to Anthony Phillips at the following address:CInP Central officePioneer awardGlenfinnan Suite, braeview House, 9/11 braeview Placeeast Kilbride, Glasgow, G74 3XHScotland, UK


Please note that all nomination documents will be copied for submission or to distribute to others.

RafaelSon YoUnG InVeSTIGaToRS aWaRD

The International College of NeuropsychopharmacologyIn 1986 ole Rafaelsen and William bunney were instrumental in establishing a CInP programme supporting the atten-dance of young scientists at the XVth CInP Congress in 1986. That programme was posthumously named the Rafaelsen fellowship award to honor Dr. Rafaelsen, who died in 1987.

The recipients of the 29th Congress awards will be chosen by an international scientific jury by early March 2014. a number of awardees will be selected and presented with awards consisting of round trip economy air travel, up to four nights accommodation, a certificate, a cash stipend including an element for ground transportation and waived registra-tion fees at the 29th CInP Congress in Vancouver, Canada.

Guidelinese The Young Investigator awards are open to individual’s world-wide, independent of nationality, sex or race.e applications must be sponsored by a CInP member.e Those nominated may be researchers or clinicians, but must have made a commitment to the field of

neuropsychopharmacology.e Individuals must have a doctorate degree, be working full-time in neuropsychopharmacology research, teaching, or

clinical activities, have not reached his/her 36th birthday in the year in which the award is made (i.e., no older than 35 years of age as of 31 December 2014).

e each awardee must commit to present a poster at the 2014 Congress.e The awardee must commit to attendance at the 2014 Congress for at least three full days.


e The nominee’s curriculum vitae including a list of publications.e a 500-word statement which summarizes the nominee’s current work activity and explains the basis for the nomination,

and include a statement of agreement to present a poster.e Sponsor’s letter of recommendation.e This completed application form.


address:

Tel: fax:


I hereby confirm that my application is complete and that I subscribe to all regulations governing the Rafaelsen fellow-ship award. You can submit your application by email, fax or post.


Please return completed applications to:Pierre blier, Chair, fellowship & awards CommitteeRafaelsen Young Investigators awardCInP Central officeGlenfinnan Suite, braeview House, 9/11 braeview Placeeast Kilbride, Glasgow, G74 3XHScotland, UK



CInP eTHICS PRIZe In PSYCHoPHaRMaColoGY

The International College of NeuropsychopharmacologyCInP is pleased to announce that in 2014 the ethics Prize in Psychopharmacology will be presented at the 29th World Congress in parallel with the other international CInP sponsored awards. The ethics Prize in Psychopharmacology will recognise an individual’s outstanding achievements in ethics research within the field of psychopharmacology as well as their contribution to the promotion of public awareness of ethics in psychopharmacology and contributions to the world-wide solution of issues and questions within the ethical practice of psychopharmacology. While the subject of ethics involves all of human behaviour; ethics within medicine and medical research, particularly within the field of psychophar-macology, raises numerous sensitive issues related to the very essence of human nature. areas included for consideration in this prize include 1) ethics of scientific responsibility in publishing in psychopharmacology; 2) conflict of interest in clinical research; 3) treatment of research subjects both human and animal; 4) informed consent in psychopharmacology research and 5) doctor patient relationships in psychopharmacology.

applicants must be nominated by a CInP member and include a CV and one to three page statement of the justification of the nomination. applications to this award will be judged by the ethics Prize Committee, an international committee of experts in the field. all submissions should be received by friday 10th January 2014. The successful applicant will re-ceive complimentary registration and up to four nights’ accommodation at the Congress Hotel.

Please address your submissions to:ethics Prize CommitteeDan Stein, Chair of the ethics Comimittee CInP Central officeGlenfinnan Suite, braeview House, 9/11 braeview Placeeast Kilbride, Glasgow, G74 3XHScotland, UK

Tel: +44 (0) 1355 244 930 fax: +44 (0) 1355 249 959 email: [email protected]


✃

29th CINP WORLD CONgRessCINP – The International College of Neuropsychopharmacology22 – 26 June 2014 • Vancouver, Canada

RegistRation FoRm

Please forward the completed form to: Please complete using block letters or typewriter

Hanser & Co gmbH Phone: +49 – 40 – 670 88 20PO Box 12 21 Fax: +49 – 40 – 670 32 8322882 Barsbütel, germany email: [email protected]

a. Personal Details

m Ms m Mrs m Mr m Dr m Prof

Family name: First name:

Institution / Department:

mailing address: m private address m institute address

street:

Postal code, City: Country:

Phone: Fax:

e-mail:

B. accompanying Person

m Ms m Mrs m Mr m Dr m Prof

Family name: First name:

For registered accompanying persons a 3 hours bus tour 'Photographic Tour of Vancouver' is included.Please mark with a cross if you want to participate.

q 22 June 2014, 14:00 –17:00 [40] q 23 June 2014, 09:30 –12:30 [41]

C. Registration Fees

Registration and Payment receiveduntil 5 February 2014

until20 may 2014

after20 may 2014

eUR

CINP Member [20] q eUR 500 [21] q eUR 600 [22] q eUR 700 eUR

Non-Member [23] q eUR 700 [24] q eUR 800 [25] q eUR 900 eUR

Young scientist * [26] q eUR 300 [27] q eUR 350 [28] q eUR 400 eUR

Delegate from Developing Country ** [29] q eUR 200 [30] q eUR 220 [31] q eUR 240 eUR

student *** [32] q eUR 110 [33] q eUR 130 [34] q eUR 150 eUR

Accompanying Person [35] q eUR 90 [35] q eUR 90 [35] q eUR 90 eUR

total eUR

* Applicants must be under 35 years of age and a copy of passport or other government-issued ID must be forwarded along with the registration.** A limited number of developing countries registrations are available. To be eligible, you must reside in one of the following countries, as classified

by the World Bank. List see page 27.*** students aged less than 35 years who are studying for a degree including first degrees, PhD or MD but who have not yet obtained their degree. They

must supply a letter from their supervisor or laboratory head to support their application for this reduced fee.

324

324

for internal use only

for internal use only

D. Social Programme

Sunday, 22 June 2014 No. of persons

Welcome Reception 19.30 h [39] free of charge for registered delegates /

accompanying persons

E. Payment

Total amount to be paid: EUR

m I have transferred the amount (free of any bank charges) of EUR on (date) to your bank:

Hanser & Co GmbH w / CINP 2014 ZB

HSH Nordbank AG

BIC: HSH NDE HH, IBAN: DE38 2105 0000 1001 2457 83

or

m I use the following credit card: m Visa m American Express m Mastercard / Eurocard

Name as indicated on the card:

Street:

Postal code, City:

Country:

Card number:

Security number: (See the back of your credit card)

Expiry date:

q I will attend the 29th CINP Congress only if my abstract has been accepted. Should my abstract not be accepted the registra-tion fee will be refunded upon my request.

q I agree that my name, institution, city and country will be published in the who is who on the internet.

I herewith accept the general conditions mentioned underneath. I agree that for the purpose of congress organisation only my personal data will be registered by using electronic data processors. My name and address will be listed in the congress list of participants and provided to sponsors and exhibitors for invitation purpose.

Date Signature

GENErAl CoNDItIoNS

registration and Payment: Registration will be confirmed if payment is received by the Congress Office by 20 May 2014. Should payment be received after this date, you will receive your confirmation at the Congress Counter in Vancouver. Please bring a copy of your bank remittance with you.

Cancellations of Congress Participation: Notice of cancellation should be sent in writing only to the Congress Office CPO HANSER SERVICE. In case of cancellation until 5 February 2014 the payment will be refunded, minus a handling charge of EUR 100. No refund will be made after 5 February 2014.

Changes to the Congress Program: In the event of cancellations by speakers or other changes in the main congress program, no full or partial refund of the registration fee can be made.

Abstract Submission: The acceptance of submitted abstracts simultaneously results in binding registration of the speaker to attend the conference. The registration fee must be paid immediately after receiving the abstract acceptance. Onsite registration for presenting authors is not possible. If the author withdraws a contribution accepted by the scientific committee and published in the abstract book, registration for the conference will be maintained and there will be no refund of the registration fees.

Force Majeure: For reasons beyond its control (such as war, strikes, lockouts, riots or any such civil disturbances, any acts of God, including but not limited to earthquakes, floods, droughts and typhoons and any other cause of circumstance of whatsoever nature beyond its control that have an impact on the arrangements, timetables or planning of 29th CINP World Congress and its corresponding activities in Vancouver, Canada), 29th CINP World Congress has the right to immediately alter or cancel the activities or events or any of the arrangements, timetables, plans or other items relating directly or indirectly thereto. No party involved shall be entitled to any compensation for damages that result from such alteration or cancellation.

liability: CPO HANSER SERVICE is liable in keeping with diligence required of a prudent businessman, according to the laws of the Federal Republic of Germany. Regardless of course in law the liability of CPO HANSER SERVICE shall be limited to damages which are caused with aforethought or by gross negligence. However, this shall not affect the liability of the Congress organizer and of the persons or organizations responsible for providing means of transport or other services. The participants take part in all excursions at their own risk. Verbal agreement can only be considered as binding when confirmed by CPO HANSER SERVICE in writing.

Place of Performance, Venue of Jurisdiction: Vancouver shall be the exclusive place of performance and Hamburg venue of jurisdiction for all parties. The laws of the Federal Republic of Germany shall apply.

aCKnoWleDGeMenTS

The organizers of the 29th CInP World Congress of neuro-psychopharmacology 2014 gratefully acknowledge the support of the following companies (as of october 2013):

Platinum Sponsor

H. lundbeck a/S

Silver Sponsors

f. Hoffmann-laRoche ltd.

Sunovion Pharmaceuticals Inc.

Sponsors

eeli lilly and CompanyeastraZeneca

www.cinp2014.comwww.cinp.org

CPo HanSeR SeRVICeHamburg officeHanser & Co GmbHZum ehrenhain 3422885 barsbüttel, Germany

Phone: +49 – 40 – 670 88 20fax: +49 – 40 – 670 32 83email: [email protected]

www.cinp2014.comwww.cinp.org

Congress and exhibition office

Documents

29th CINP WORLD CONGRESS OF NEUROPSYCHOPHARMACOLOGY · 2017-06-22 · 29th CINP WORLD CONGRESS OF NEUROPSYCHOPHARMACOLOGY CInP – The International College of neuropsychopharmacology